Antibacterial drug discovery targeting the lipopolysaccharide biosynthetic enzyme LpxC

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 7, 2016, Pages

  Erwin, Alice L ^a  

^a Erwin Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL ENZYME; BACTERIUM LIPOPOLYSACCHARIDE; LIPID A; LPXC PROTEIN; UNCLASSIFIED DRUG; ACYLTRANSFERASE; AMIDASE; BACTERIAL PROTEIN; ENZYME INHIBITOR; LPXC DEACETYLASE, PSEUDOMONAS; LPXL PROTEIN, BACTERIA;

ARTICLE; DRUG TARGETING; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; LIPOGENESIS; NONHUMAN; OUTER MEMBRANE; PSEUDOMONAS AERUGINOSA; SYNTHESIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS;

ACYLTRANSFERASES; AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG DISCOVERY; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; LIPID A; PSEUDOMONAS AERUGINOSA;

EID: 84977554126     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025304     Document Type: Article

References (79)

1. Abramite JA, Brown MF, Chen JM, Melnick MJ, Montgomery JI, Reilly U. 2014. Isoxazole derivatives useful as antibacterial agents. U.S. Patent 2014024690 (A1).
2. Andersen NH. 2003. Design of LpxC, UDP-(3-O-acyl)-N-acetylglucosamine deacetylase, inhibitors and their antibacterial activity. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, September 14-17.
3. Andersen NH, Bowman J, Erwin A, Harwood E, Kline T, Mdluli K, Ng S, Pfister KB, Shawar R, Wagman AS, et al. 2011. Antibacterial agents. U.S. Patent 2011172174 (A1).
4. Anderson MS, Bull HG, Galloway SM, Kelly TM, Mohan S, Radika K, Raetz CR. 1993. UDP-N-acetylglucosamine acyltransferase of Escherichia coli. The first step of endotoxin biosynthesis is thermodynamically unfavorable. J Biol Chem 268: 19858-19865.
5. Badal R, Hoban D, Hackel M, Bouchillon S, Serio A. 2013. In vitro activity of ACHN-975 against 1,050 non-fermentative Gram-negative bacilli. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract E-614. Denver, September 10-13.
6. Barb AW, Jiang L, Raetz CRH, Zhou P. 2007a. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. Proc Natl Acad Sci 104: 18433-18438.
7. Barb AW, McClerren AL, Snehelatha K, Reynolds CM, Zhou P, Raetz CRH. 2007b. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Biochemistry 46: 3793-3802.
8. Barb AW, Leavy TM, Robins LI, Guan Z, Six DA, Zhou P, Hangauer MJ, Bertozzi CR, Raetz CRH. 2009. Uridine- based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC. Biochemistry 48: 3068-3077.
9. Beall B, Lutkenhaus J. 1987. Sequence analysis, transcrip-tional organization, and insertional mutagenesis of the envA gene of Escherichia coli. J Bacteriol 169: 5408-5415.
10. Benenato K, Choy A, Hale M, Hill P, Marone V, Miller M. 2010. Hydroxamic acid derivatives as Gram-negative antibacterial agents. Patent WO2010100475 (A1).
11. Bodewits K, Raetz CR, Govan JR, Campopiano DJ. 2010. Antimicrobial activity of CHIR-090, an inhibitor of lipo-polysaccharide biosynthesis, against the Burkholderia cepacia complex. Antimicrob Agents Chemother 54: 3531-3533.
12. Bornheim L, McKinnell J, Fuchs-Knotts T, Boggs J, Kostrub CF. 2013. Preclinical safety evaluation of the novel LpxC inhibitor ACHN-975 in rat and monkey. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract F-1231. Denver, September 10-13.
13. Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Bar-ham RA, Che Y, Chen JM, Collantes EM, Chung SW, et al. 2012. Potent inhibitors of LpxC for the treatment of Gram-negative infections. J Med Chem 55: 914-923.
14. Brown MF, Che Y, Marfat A, Melnick MJ, Montgomery JI, Reilly U. 2014a. N-link hydroxamic acid derivatives useful as antibacterial agents. U.S. Patent 2014343031 (A1).
15. Brown MF, Chen JM, Melnick MJ, Montgomery JI, Reilly U. 2014b. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents. U.S. Patent 2014038975 (A1).
16. Bulitta JB, Kuhn M, Finegan S, George D, Barham R, Had-dish-Berhane N, Betts A, Brown M, Hanna D, Montgomery J, et al. 2011. Optimizing synergy between a new LpxC inhibitor (PF1090) and polymyxin B nonapeptide (PBN) by mechanism-based modeling to efficiently support drug development. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract A2-1170. Chicago, September 17-20.
17. Caughlan RE, Jones AK, DeLucia AM, Woods AL, Xie L, Ma B, Barnes SW, Walker JR, Sprague ER, Yang X, et al. 2012. Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the Gram-negative pathogen Pseudomonas aeruginosa. Antimicrob Agents Chemother 56: 17-27.
18. Chapoux G, Gauvin J-C, Panchaud P, Specklin J-L, Surivet J- P, Schmitt C. 2015. 1,2-dihydro-3H-pyrrolo[1,2-C]imi-dazol-3-one derivatives and their use as antibacterial agents. Patent WO2015132228 (A1).
19. Chen MH, Steiner MG, de Laszlo SE, Patchett AA, Anderson MS, Hyland SA, Onishi HR, Silver LL, Raetz CR. 1999. Carbohydroxamido-oxazolidines: Antibacterial agents that target lipid A biosynthesis. Bioorg Med Chem Lett 9: 313-318.
20. Clements JM, Coignard F, Johnson I, Chandler S, Palan S, Waller A, Wijkmans J, Hunter MG. 2002. Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother 46: 1793-1799.
21. Coggins BE, Li X, McClerren AL, Hindsgaul O, Raetz CRH, Zhou P. 2003. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. Nat Struct Biol 10: 645-651.
22. Cohen SM, Puerta DT, Perez C. 2015. Inhibitors of LpxC. Patent WO2015085238 (A1).
23. Dowhan W. 2011. The Raetz pathway for lipid A biosynthesis: Christian Rudolf Hubert Raetz, MD PhD, 1946-2011. J Lipid Res 52: 1857-1860.
24. Emiola A, George J, Andrews SS. 2014. A complete pathway model for lipid A biosynthesis in Escherichia coli. PLoS ONE 10: e0121216.
25. Erwin AL. 2003. LpxC inhibitors: New class of antibiotics for serious Gram-negative infections. In 8th International Antibacterial Drug Discovery & Development Summit, Princeton, NJ, March 24-25.
26. Fu J, Karur S, Madera AM, Pecchi S, Sweeney ZK, Tjandra M, Yifru A. 2014. Hydroxamic acid derivatives as Lpxc inhibitors for the treatment of bacterial infections. Patent WO2014160649 (A1).
27. Fu J, Lee P, Madera AM, Sweeney ZK. 2015. Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections. Patent WO2015066413 (A1).
28. Fuhrer F, Langklotz S, Narberhaus F. 2006. The C-terminal end of LpxC is required for degradation by the FtsH protease. Mol Microbiol 59: 1025-1036.
29. Gauvin J-C, Mirre A, Ochala E, Surivet J-P. 2015. Antibac-terial 2H-indazole derivatives. Patent WO2015036964(A1).
30. Hale MR, Hill P, Lahiri S, Miller MD, Ross P, Alm R, Gao N, Kutschke A, Johnstone M, Prince B, et al. 2013. Exploring the UDP pocket of LpxC through amino acid analogs. Bioorg Med Chem Lett 23: 2362-2367.
31. Hubschwerlen C, Ochala E, Specklin J-L, Surivet J-P. 2015. Antibacterial 1H-indazole and 1H-indole derivatives. Patent WO2015091741 (A1).
32. Jain R, Gordeev M, Lewis J, Francavilla C. 2011. N-hydrox- yamide derivatives possessing antibacterial activity. Patent EP2338878 (A2).
33. Kasar R, Linsell MS, Aggen JB, Lu QJ, Wang D, Church T, Moser HE, Patten PA. 2012. Hydroxamic acid derivatives and their use in the treatment of bacterial infections. Patent WO2012154204 (A1)
34. Kline T, Andersen NH, Harwood EA, Bowman J, Malanda A, Endsley S, Erwin AL, Doyle M, Fong S, Harris AL, et al. 2002. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC. J Med Chem 45: 3112-3129.
35. Kresge N, Simoni RD, Hill RL. 2011. The lipid A assembly pathway: The work of Christian Raetz. J Biol Chem 286: e6-e8.
36. Langklotz S, Schakermann M, Narberhaus F. 2011. Control of lipopolysaccharide biosynthesis by FtsH-mediated proteolysis of LpxC is conserved in enterobacteria but not in all Gram-negative bacteria. J Bacteriol 193: 1090-1097.
37. Lee C-J, Liang X, Chen X, Zeng D, Joo SH, Chung HS, Barb AW, Swanson SM, Nicholas RA, Li Y, et al. 2011. Species-specific and inhibitor-dependent conformations of LpxC: Implications for antibiotic design. Chem Biol 18: 38-47.
38. Lee C-J, Liang X, Gopalaswamy R, Najeeb J, Ark ED, Toone EJ, Zhou P. 2014. Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC. ACS Chem Biol 9: 237-246.
39. Leive L. 1974. The barrier function of the gram-negative envelope. Ann NY Acad Sci 235: 109-129.
40. Liang X, Lee C-J, Chen X, Chung HS, Zeng D, Raetz CRH, Li Y, Zhou P, Toone EJ. 2011. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold. Bioorg Med Chem 19: 852-860.
41. Liang X, Lee C-J, Zhao J, Toone EJ, Zhou P. 2013. Synthesis, structure and antibiotic activity of aryl-substituted LpxC inhibitors. J Med Chem 56: 6954-6966.
42. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, et al. 2012. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 3: e00312-12.
43. Linsell MS, Aggen JB, Dozzo P, Hildebrandt DJ, Cohen F, Kasar RA, Kane TR, Gliedt MJ, McEnroe GA. 2014. Antibacterial agents. Patent WO2014165075 (A1).
44. Mansoor UF, Reddy PA, Siddiqui MA. 2011a. Urea derivatives as antibacterial agents. U.S. Patent 2011212080(A1).
45. Mansoor UF, Vitharana D, Reddy PA, Daubaras DL, McNicholas P, Orth P, Black T, Siddiqui MA. 2011b. Design and synthesis of potent Gram-negative specific LpxC inhibitors. Bioorg Med Chem Lett 21: 1155-1161.
46. McAllister LA, Montgomery JI, Abramite JA, Reilly U, Brown MF, Chen JM, Barham RA, Che Y, Chung SW, Menard CA, et al. 2012. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents. Bioorg Med Chem Lett 22: 6832-6838.
47. McClerren AL, Endsley S, Bowman JL, Andersen NH, Guan Z, Rudolph J, Raetz CRH. 2005. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin. Biochemistry 44: 16574-16583.
48. Mdluli KE, Witte PR, Kline T, Barb AW, Erwin AL, Mansfield BE, McClerren AL, Pirrung MC, Tumey LN, Warrener P, et al. 2006. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrob Agents Chemother 50: 2178-2184.
49. Mochalkin I, Knafels JD, Lightle S. 2008. Crystal structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor. Protein Sci 17: 450-457.
50. Moffatt JH, Harper M, Harrison P, Hale JDF, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, et al. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54: 4971-4977.
51. Montgomery JI, Brown MF, Reilly U, Price LM, Abramite JA, Arcari J, Barham R, Che Y, Chen JM, Chung SW, et al. 2012. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious Gram-negative infections. J Med Chem 55: 1662-1670.
52. Murphy-Benenato KE, Olivier N, Choy A, Ross PL, Miller MD, Thresher J, Gao N, Hale MR. 2014. Synthesis, structure, and SAR of tetrahydropyran-based LpxC inhibitors. ACS Med Chem Lett 5: 1213-1218.
53. Normark S, Boman HG, Matsson E. 1969. Mutant of Escherichia coli with anomalous cell division and ability to de-crease episomally and chromosomally mediated resistance to ampicillin and several other antibiotics. J Bacteriol 97: 1334-1342.
54. Ogura T, Inoue K, Tatsuta T, Suzaki T, Karata K, Young K, Su LH, Fierke CA, Jackman JE, Raetz CR, et al. 1999. Balanced biosynthesis of major membrane components through regulated degradation of the committed enzyme of lipid A biosynthesis by the AAA protease FtsH (HflB) in Escherichia coli. Mol Microbiol 31: 833-844.
55. Onishi HR, Pelak BA, Gerckens LS, Silver LL, Kahan FM, Chen MH, Patchett AA, Galloway SM, Hyland SA, An- derson MS, et al. 1996. Antibacterial agents that inhibit lipid A biosynthesis. Science 274: 980-982.
56. Osborn MJ, Gander JE, Parisi E. 1972. Mechanism of assembly of the outer membrane of Salmonella typhimurium. Site of synthesis of lipopolysaccharide. J Biol Chem 247: 3973-3986.
57. Patten PA, Armstrong ES. 2012. Antibacterial compositions. U.S. Patent 2012283175 (A1).
58. Patterson B, Lu Q, Aggen J, Dozzo P, Kasar R, Linsell M, Kane T, Gliedt M, Hildebrandt D, McEnroe G, et al. 2015a. Antibacterial agents. Patent EP2847162 (A1), abstract of corresponding document WO2013170030 (A1).
59. Patterson BD, Lu Q, Aggen JB, Dozzo P, Kasar RA, Linsell MS, Kane TR, Gliedt MJ, Hildebrandt DJ, McEnroe Ga, et al. 2015b. Antibacterial agents. Patent EP2847168 (A1), abstract of corresponding document WO2013170165(A1).
60. Raetz CR. 1993. Bacterial endotoxins: Extraordinary lipids that activate eucaryotic signal transduction. J Bacteriol 175: 5745-5753.
61. Rafanan N, Lopez S, Hackbarth C, Maniar M, Margolis P, Wang W, Yuan Z, Jain R, Jacobs J, Trias J. 2000. Resistance in E.coli to LpxC inhibitor L-161,240 is due to mutations in the lpxC gene. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract 2026. Toronto, September 17-20.
62. Raju B, Odowd H, Gao H, Patel D, Trias J. 2004. N-hydrox-yamide derivatives possessing antibacterial activity. WO2004007444 (A2).
63. Reilly U, Melnick MJ, Brown MF, Plummer MS, Montgomery JI, Che Y, Price LM. 2014. Fluoro-pyridinone derivatives useful as antibacterial agents. U.S. Patent 2014057919 (A1).
64. Reyes N, McKinnell J, Fuchs-Knotts T, Kostrub CF, Cirz R. 2013. ACHN-975 demonstrates potent efficacy against Gram-negative bacteria in the neutropenic mouse thigh infection model. 53rd Interscience Conference on Antimi-crobial Agents and Chemotherapy (ICAAC), Abstract F-1229. Denver, September 10-13.
65. Ruiz N, Kahne D, Silhavy TJ. 2009. Transport of lipopoly-saccharide across the cell envelope: The long road of discovery. Nat Rev Microbiol 7: 677-683.
66. Sampson BA, Misra R, Benson SA. 1989. Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics 122: 491-501.
67. Serio AW, Kubo A, Lopez S, Gomez M, Corey VC, Andrews L, Schwartz MA, Kasar R, McEnroe G, Aggen J, et al. 2013. Structure, potency and bactericidal activity of ACHN-975, a first-in-class LpxC inhibitor. 53rd Inter- science Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract F-1226. Denver, CO, September 10-13.
68. Shen X, Johnson NV, Jones AK, Barnes SW, Walker JR, Ranjitkar S, Woods AL, Six DA, Dean CR. 2014. Genetic characterization of the hypersusceptible Pseudomonas aeruginosa strain Z61; identification of a defect in LptE. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Abstract C-105. Washington, DC, September 5-9.
69. Sorensen PG, Lutkenhaus J, Young K, Eveland SS, Anderson MS, Raetz CR. 1996. Regulation of UDP-3-O-[R-3-hy- droxymyristoyl]-N-acetylglucosamine deacetylase in Escherichia coli. The second enzymatic step of lipid A biosynthesis. J Biol Chem 271: 25898-25905.
70. Takashima H, Yoshinaga M, Ushiki Y, Tsuruta R, Urabe H, Tanikawa T, Tanabe K, Baba Y, Yokotani M, Kawaguchi Y, et al. 2008. Novel hydroxamic acid derivative. Patent WO2008105515 (A1).
71. Tomaras AP, McPherson CJ, Kuhn M, Carifa A, Mullins L, George D, Desbonnet C, Eidem TM, Montgomery JI, Brown MF, et al. 2014. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens. mBio 5: e01551-01514.
72. Walkup GK, You Z, Ross PL, Allen EKH, Daryaee F, Hale MR, O’Donnell J, Ehmann DE, Schuck VJA, Buurman ET, et al. 2015. Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nat Chem Biol 11: 416-423.
73. Whittington DA, Rusche KM, Shin H, Fierke CA, Christianson DW. 2003. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc Natl Acad Sci 100: 8146-8150.
74. Young K, Silver LL, Bramhill D, Cameron P, Eveland SS, Raetz CR, Hyland SA, Anderson MS. 1995. The envA permeability/cell division gene of Escherichia coli encodes the second enzyme of lipid A biosynthesis. UDP- 3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine de- acetylase. J Biol Chem 270: 30384-30391.
75. Zeng D, Zhao J, Chung HS, Guan Z, Raetz CRH, Zhou P. 2013. Mutants resistant to LpxC inhibitors by rebalancing cellular homeostasis. J Biol Chem 288: 5475-5486.
76. Zhou P, Toone E, Nicholas R. 2015a. 2-Piperidinyl substituted N,3-dihydroxybutanamides. Patent WO2015024016(A2).
77. Zhou P, Toone E, Nicholas R. 2015b. Antibacterial compounds. Patent WO2015024021 (A2).
78. Zhou P, Toone E, Nicholas R. 2015c. Substituted hydroxamic acid compounds. Patent WO2015024010 (A2).
79. Zimmermann W. 1980. Penetration of b-lactam antibiotics into their target enzymes in Pseudomonas aeruginosa: Comparison of a highly sensitive mutant with its parent strain. Antimicrob Agents Chemother 18: 94-100.